Table 1

Baseline characteristics and posology of rivaroxaban

DVT/PE (N=1532)
Baseline characteristics
 Age (years), median (IQR)63 (48–73)
 Gender (male), n (%)836 (54.6)
 BMI, median (IQR)28.2 (24.8–32.6)*
HAS-BLED, n (%)
 Hypertension†307 (20.0)
 Abnormal renal function26 (1.7)
 Abnormal liver function33 (2.2)
 History of stroke70 (4.6)
 History of bleeding or predisposition322 (21.0)
 Labile INRNA
 Age ≥65 years701 (45.8)
 Drug therapy‡388 (25.3)
 Alcohol (≥8 drinks/week)89 (5.8)
 HAS-BLED score, median (IQR)1 (0–2)
Score, n (%)
 0482 (31.5)
 1498 (32.5)
 2314 (20.5)
 3164 (10.7)
 457 (3.7)
 512 (0.8)
 65 (0.3)
 70 (0.0)
 80 (0.0)
 History of congestive heart failure/left ventricular dysfunction51 (3.3)
 History of diabetes mellitus154 (10.1)
 History of malignancy (any)162 (10.6)
 Recent malignancy (within 3 months§)48 (3.1)
Prior use of antithrombotic¶ (within 28 days of start of treatment), n (%)
 Any1001 (65.3)
 Low-molecular-weight heparin**862 (56.3)
 Direct switching from prior antithrombotic,¶ n (%)831 (54.2)
 Low-molecular-weight heparin**707 (85.1)
Starting total daily dose, n (%)
 102 (0.1)
 15154 (10.2)
 20192 (12.8)
 251 (0.1)
 301154 (76.8)
 Missing29 (−)
  • *BMI was missing for 337 patients (22.0%).

  • †Uncontrolled, >160 mm Hg systolic.

  • ‡Concomitant antiplatelets or non-steroidal anti-inflammatory drugs.

  • §Within 3 months of start of treatment.

  • ¶Includes oral/parenteral anticoagulants and antiplatelets.

  • **Includes bemiparin, enoxaparin, tinzaparin and dalteparin.

  • ††Where specified provided, unless otherwise indicated.

  • BMI, body mass index; DVT, deep vein thrombosis; HAS-BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding predisposition, Labile international normalised ratios, Elderly, Drug/alcohol usage; INR, international normalised ratio; NA, not applicable; PE, pulmonary embolism.